Renalytix Plc Regulatory News (RENX)

Renalytix plc

("Renalytix" or the "Company")

Directorate Change

Robert Naylor appointed as Non-Executive Director

LONDON and NEW YORK, 2 December 2024 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the appointment of Robert Naylor as Non-Executive Director with immediate effect.

Robert has 29 years' experience in capital markets, specialising in both the life sciences and investment companies sectors. Robert is currently CEO and Co-Founder of Intuitive Investments Group plc, a London Stock Exchange Specialist Funds Segment investment company providing investors with exposure to fast growing technology and life sciences businesses. Robert is also Non-Executive Director of NIOX Group PLC, a company dedicated to improving asthma diagnosis and management, and PRS REIT plc, a FTSE 250 closed-ended real estate investment company which invests in high-quality, new build, family homes in the private rented sector.

Previously, Robert was Chairman of Hipgnosis Songs Fund Limited, a FTSE 250 company, which was subject to a recommended cash offer by a newly-formed company indirectly wholly-owned by investment funds advised by affiliates of Blackstone Inc. Robert was Chairman of Round Hill Music Royalty Fund Limited and oversaw its sale to a company directly owned by Alchemy Copyrights, LLC, trading as Concord. Earlier in his career Robert held various positions within JP Morgan Asset Management Limited, Panmure Gordon (UK) Limited and Cenkos Securities plc. Robert is a qualified chartered accountant, having started his career with Ernst & Young in 1996.

James McCullough, CEO of Renalytix plc, commented: "It is a pleasure to have Robert join the Board of Renalytix, bringing with him a wealth of knowledge in the life sciences sector. Robert's capital markets experience and insight is invaluable to us as an AIM listed business.

"Renalytix offers investors unique access to a world-leading kidney prognostic test, KidneyintelX.dkd: the only test to be FDA approved, granted full Medicare reimbursement at $950 per test; available to approximately 14 million US diabetic kidney disease patients; and able to address the needs of approximately 260 million diabetic kidney disease patients globally."

Additional Disclosures Required under the AIM Rules for Companies

Robert Graham Naylor (aged 50) has held the following directorship or partnerships in the past five years:

Robert Naylor and persons closely associated (as defined under MAR) with Mr Naylor currently hold 588,055 ordinary shares of £0.0025 each in the Company.

Save as disclosed above, there is no further information to be disclosed in respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.

For further information, please contact:

About Renalytix

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com